Navigation Links
DrugRisk Update: New Study Warns of Cancer in Byetta Side Effects
Date:5/4/2013

Los Angeles, CA (PRWEB) May 04, 2013

The diabetes drug safety advocates at DrugRisk.com are announcing updated information for patients who have taken the medication Byetta. A recent study suggests the drug may have higher occurrence rates of pancreatic cancer and thyroid cancer than traditional treatments.

DrugRisk was created to improve the safety of those taking popular prescription drugs by providing the latest warnings, recalls, studies and legal news. Patients can see if others are experiencing similar side effects and decide if they need legal advice.

Byetta is a twice-daily injectable medication released in 2005 to help those with type-2 diabetes control blood sugar. It generated sales of over $300 million last year, when it was purchased with Amylin Pharmaceuticals by Bristol-Myers Squibb*.

However, DrugRisk has added a 2011 study from UCLA indicating Byetta could increase the risk of pancreatic cancer by 290% and thyroid cancer by 473%**. The Journal for the American Medical Association also recently published findings showing these drugs can double the risk of pancreatitis, a major risk factor for pancreatic cancer***.

Now, DrugRisk has added a new report by the Institute for Safe Medication Practices, which found in an analysis of FDA reports that patients were over 20 times as likely to report pancreatitis, pancreatic cancer or thyroid cancer from Januvia than from traditional diabetes treatment like metformin****.

Due to the number of patients filing a Byetta lawsuit alleging cancer, lawyers have asked that cases be consolidated to a special federal multi-district court in California****. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).

Anyone affected by cancer after taking Byetta is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Byetta lawsuits.

For more information on the research, side effects and litigation news related to Byetta and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
**Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
***JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537
****Institute for Safe Medication Practices, 4/18/13; ismp.org/QuarterWatch/pdfs/2012Q3.pdf
*****JPML, 4/5/13; cdn.aboutlawsuits.com/wp-content/uploads/2013-04-05-Incretin-Mimetics-MDL.pdf

Read the full story at http://www.prweb.com/releases/byetta-lawsuit/side-effects/prweb10699747.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
2. DrugRisks News Update: Bayer Loses Yaz Patent as Blood Clot Settlements Continue
3. DrugRisk Update: Court Asks for Pradaxa Lawsuit Test Cases
4. DrugRisks Adds Update From Court Ordering Mediation of Stryker Hip Lawsuits
5. DrugRisk Announces Launch of Byetta Cancer Resource Center
6. DrugRisks Update: Federal Court Schedules First Mirena Lawsuit Hearing
7. DrugRisk Announces Addition of Januvia Cancer Resource Center
8. DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week
9. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
10. DrugRisk Announces Launch of DePuy Hip Resource Center
11. DrugRisk Update: Mirena Maker Asks to Keep Lawsuits With Local Court, Judge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... First Choice ... celebrating the one year anniversary of its Houston-Fallbrook facility. , “We are ... Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has been a ...
(Date:9/22/2017)... ... ... “Letters From Home”: a moving compilation of letters that remind readers of the ... is the creation of published author, John Allred, a passionate leader of ministry to ... who has traveled and ministered on four continents. , “It is my hope and ...
(Date:9/21/2017)... , ... September 21, 2017 , ... With ProSlideshow Portrait ... and easy to do. Users can select from up to two layers of subject ... click of a mouse all within Final Cut Pro X. , With ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... learn with Infinity Behavioral Health Services for professionals in the addiction treatment industry ... Payer Audit . , Insurance companies and state and federal governments are ...
(Date:9/21/2017)... ... September 21, 2017 , ... Bill Howe Plumbing’s mission is to create an ... to the community. For over 37 years, they have operated with their mission at ... in San Diego. They were chosen as the Best San Diego plumber in ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: